|
Volumn 452, Issue 3, 1999, Pages 160-164
|
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase
|
Author keywords
Atherosclerosis; Gene regulation; Hypolipidemic drug; Sterol response element binding protein 1 adipocyte determination and differentiation factor 1; Triglyceride
|
Indexed keywords
ANTILIPEMIC AGENT;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LIPOPROTEIN LIPASE;
LOW DENSITY LIPOPROTEIN RECEPTOR;
SIMVASTATIN;
STATINE DERIVATIVE;
STEROL REGULATORY ELEMENT BINDING PROTEIN;
VERY LOW DENSITY LIPOPROTEIN;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
ATHEROSCLEROSIS;
CHOLESTEROL METABOLISM;
CONTROLLED STUDY;
DRUG MECHANISM;
ENZYME ACTIVITY;
LIPOLYSIS;
MALE;
NONHUMAN;
ORAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
RAT;
TRIACYLGLYCEROL BLOOD LEVEL;
ANIMALS;
APOLIPOPROTEIN A-I;
APOLIPOPROTEIN A-II;
APOLIPOPROTEIN C-III;
APOLIPOPROTEINS C;
CHOLESTEROL;
CHOLESTEROL, HDL;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
LIPOPROTEIN LIPASE;
MALE;
RATS;
RATS, SPRAGUE-DAWLEY;
SIMVASTATIN;
TRIGLYCERIDES;
|
EID: 0033006201
PISSN: 00145793
EISSN: None
Source Type: Journal
DOI: 10.1016/S0014-5793(99)00632-8 Document Type: Article |
Times cited : (83)
|
References (31)
|